title: Observations on the effects of Suppressor of Cytokine Signaling 7 (SOCS7) knockdown in breast cancer cells: their in vitro response to Insulin Like Growth Factor I (IGF-I).
abstract: OBJECTIVE
  Suppressor of cytokine signaling 7 (SOCS7) is a member of the SOCS family and is known to interact with phospholipase Cγ-1 (PLCγ-1), one of the insulin-like growth factor-I (IGF-I) receptor downstream molecules. In this study, we sought to observe the effect of knocking down SOCS7 gene on breast cancer cells in vitro growth and migration and to elucidate whether this involves IGF-I-PLCγ1 route using the PLCγ-1 blocker U73122.
  
  
  METHODS
  Suitable breast cancer cells (MCF7 and MDA-MB-231) were transfected with anti-SOCS7 ribozymal transgene, to create sub-lines with SOCS7 knockdown verified by RT-PCR. The growth and migration of the cells were evaluated in the presence or absence of IGF-I and PLCγ-1 inhibitor using growth assay, scratch-wound and electrical cell impedance sensing (ECIS) migration assays.
  
  
  RESULTS
  IGF-I treatment produced more pronounced influence on MCF7 growth and migration and on MDA-MB-231 migration when SOCS7 gene was knocked down in both lines (p < 0.05). The absence of IGF-I-induced growth response in MDA-MB-231 could be due to the intrinsic characteristics of these cells. PLCγ-1 pharmacological inhibition during their in vitro migration seemed to only occur when SOCS7 gene was knocked down.
  
  
  CONCLUSIONS
  To the best of our knowledge, this is the first report of the SOCS7 regulatory role in IGF-I induced in vitro functions in ER-positive and ER-negative breast cancer cells. IGF-I treatment and SOCS7 loss have synergistically resulted in increased growth and migration of MCF7 and in increased migration of MDA-MB-231 cells. The migratory effects could be due to a precise anti-PLCγ-1 role.
authors.affiliation: St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK, wsasi2003@yahoo.co.uk.
authors.forename: W
authors.initials: W
authors.lastname: Sasi
authors.forename: L
authors.initials: L
authors.lastname: Ye
authors.forename: W G
authors.initials: WG
authors.lastname: Jiang
authors.forename: K
authors.initials: K
authors.lastname: Mokbel
authors.forename: A
authors.initials: A
authors.lastname: Sharma
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics*; D055785:Gene Knockdown Techniques; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D009687:Nuclear Proteins / Q000235:genetics*; D050826:Suppressor of Cytokine Signaling Proteins / Q000235:genetics*; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D009687:Nuclear Proteins; C108775:SOCS7 protein, human; D050826:Suppressor of Cytokine Signaling Proteins; D007334:Insulin-Like Growth Factor I
references.citation: Mol Cell Biol. 2002 Jul;22(13):4567-78
references.pmid: 12052866
references.citation: J Clin Invest. 1989 Nov;84(5):1418-23
references.pmid: 2553774
references.citation: Cell Signal. 2012 Aug;24(8):1515-21
references.pmid: 22481093
references.citation: Biochem Biophys Res Commun. 1997 Oct 20;239(2):488-92
references.pmid: 9344857
references.citation: J Biol Chem. 1997 Jun 13;272(24):15442-51
references.pmid: 9182576
references.citation: Mol Endocrinol. 2008 Apr;22(4):965-77
references.pmid: 18165436
references.citation: J Endocrinol. 2001 Oct;171(1):153-62
references.pmid: 11572799
references.citation: J Biol Chem. 2002 Nov 1;277(44):42394-8
references.pmid: 12228220
references.citation: Clin Cancer Res. 2005 Aug 15;11(16):6012-9
references.pmid: 16115946
references.citation: J Gen Virol. 2010 Jul;91(Pt 7):1678-86
references.pmid: 20357037
references.citation: J Biol Chem. 1998 Apr 17;273(16):9994-10003
references.pmid: 9545345
references.citation: Biochem Biophys Res Commun. 1988 Jul 15;154(1):326-31
references.pmid: 2969239
references.citation: Clin Immunol. 2009 Aug;132(2):277-84
references.pmid: 19427817
references.citation: Cell Commun Signal. 2009 Feb 02;7:1
references.pmid: 19187548
references.citation: Mol Cell Biochem. 1998 May;182(1-2):3-11
references.pmid: 9609109
references.citation: Cancer Metastasis Rev. 1998-1999;17(4):383-90
references.pmid: 10453282
references.citation: Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11713-7
references.pmid: 8265614
references.citation: Mol Cell Biol. 1995 Mar;15(3):1169-74
references.pmid: 7862111
references.citation: Clin Cancer Res. 1999 Aug;5(8):2251-60
references.pmid: 10473113
references.citation: Cell. 2007 Sep 7;130(5):837-50
references.pmid: 17803907
references.citation: J Mammary Gland Biol Neoplasia. 2000 Jan;5(1):95-105
references.pmid: 10791772
references.citation: J Biol Chem. 2005 Apr 8;280(14):13817-23
references.pmid: 15677474
references.citation: EMBO J. 1992 Sep;11(9):3469-79
references.pmid: 1380456
references.citation: Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10435-9
references.pmid: 1683701
references.citation: J Clin Invest. 1994 Mar;93(3):1266-74
references.pmid: 8132765
references.citation: Mol Cell Biol. 1993 Nov;13(11):6889-96
references.pmid: 7692233
references.citation: Clin Exp Metastasis. 2003;20(4):285-90
references.pmid: 12856715
references.citation: Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1554-9
references.pmid: 14747654
references.citation: Cancer Res. 2001 Sep 15;61(18):6747-54
references.pmid: 11559546
references.citation: Int J Cancer. 2000 Nov 20;89(6):506-13
references.pmid: 11102895